Hydrogen therapy and more particularly a composition having: hydride able and intended to dissolve on contact with an aqueous medium and therefore to release dihydrogen, and a formulation agent of the hydride. The formulation agent configured to bring the hydride into contact with an environment of the composition in at least one physiological condition observable in a human or non-human animal body. Thus, by degradation of the formulation agent and dissolution of the hydride, the composition allows releasing dihydrogen in a dissolved form in a targeted portion of the human or non-human animal body.

The present invention concerns compositions for rinsing the nasal cavity and the sinus cavities for curative or prophylactic treatments of acute and/or chronic rhinitis, and acute and/or chronic sinusitis, comprising: sodium chloride and/or potassium chloride; quercetin, and at least one active agent of the polyphenolic group chosen from the compounds: quercetin-4′-glycoside, 2-(3,4-dihydroxybenzoyl)-2,4,6-trihydroxy-3(2H)-benzofuranone, protocatechuic acid; and wherein the quercetin is in the anhydrous form with an approximate molecular mass of 302 g/mol, or in the form of quercetin hydrate with an approximate molecular mass of 320 g/mol, or in the form of quercetin dihydrate with an approximate molecular mass of 338 g/mol. The present invention also relates to the methods for preparing these compositions and the method for treating acute and chronic rhinosinusitis using these compositions.

The present invention concerns compositions for rinsing the nasal cavity and the sinus cavities for curative or prophylactic treatments of acute and/or chronic rhinitis, and acute and/or chronic sinusitis, comprising: sodium chloride and/or potassium chloride; quercetin, and at least one active agent of the polyphenolic group chosen from the compounds: quercetin-4′-glycoside, 2-(3,4-dihydroxybenzoyl)-2,4,6-trihydroxy-3(2H)-benzofuranone, protocatechuic acid; and wherein the quercetin is in the anhydrous form with an approximate molecular mass of 302 g/mol, or in the form of quercetin hydrate with an approximate molecular mass of 320 g/mol, or in the form of quercetin dihydrate with an approximate molecular mass of 338 g/mol. The present invention also relates to the methods for preparing these compositions and the method for treating acute and chronic rhinosinusitis using these compositions.

A decolonization drug, a preparation method thereof and an application thereof. The decolonization drug is non-antibiotic, simple and convenient to use, and can be used systemically, and has more types of sterilization; The decolonization drug involved in the invention contains added special components, which can improve the bactericidal performance of the drug through the activator effect; The decolonization drug is suitable for use in adults and sensitive populations, including the elderly, pregnant women, infants, children, etc.; especially as a mucosal drug for nasal mucosa, oral mucosa, ocular mucosa, abdominal mucosa, genital mucosa, etc., and can also be used as a bactericidal drug in other medical fields, including diabetic foot, burns, surgical site infections (SSIs), etc.

A decolonization drug, a preparation method thereof and an application thereof. The decolonization drug is non-antibiotic, simple and convenient to use, and can be used systemically, and has more types of sterilization; The decolonization drug involved in the invention contains added special components, which can improve the bactericidal performance of the drug through the activator effect; The decolonization drug is suitable for use in adults and sensitive populations, including the elderly, pregnant women, infants, children, etc.; especially as a mucosal drug for nasal mucosa, oral mucosa, ocular mucosa, abdominal mucosa, genital mucosa, etc., and can also be used as a bactericidal drug in other medical fields, including diabetic foot, burns, surgical site infections (SSIs), etc.

The present invention relates to stable therapeutic compositions of pharmaceutical grade acids and pH buffering agents. The present invention also is directed to methods of treatment for mitochondrial disorders, metabolic conditions, diabetic conditions, and cardiovascular conditions, by administration of compositions of the present disclosure.

The present invention relates to stable therapeutic compositions of pharmaceutical grade acids and pH buffering agents. The present invention also is directed to methods of treatment for mitochondrial disorders, metabolic conditions, diabetic conditions, and cardiovascular conditions, by administration of compositions of the present disclosure.

Formulations and uses thereof are provided for supporting human natural defense against viral infections as well as providing treatment for viral infections susceptible to a lysosomotropic agent. Administration of a lysosomotropic agent, such as ammonium chloride (NH.sub.4Cl), can militate against the uncoating of viruses within the lysosome of an infected cell and thereby minimize infection by viruses whose replication cycle relies upon an uncoating step in such a manner.

Formulations and uses thereof are provided for supporting human natural defense against viral infections as well as providing treatment for viral infections susceptible to a lysosomotropic agent. Administration of a lysosomotropic agent, such as ammonium chloride (NH.sub.4Cl), can militate against the uncoating of viruses within the lysosome of an infected cell and thereby minimize infection by viruses whose replication cycle relies upon an uncoating step in such a manner.

An object of a first aspect of the present invention is to provide a radical generating catalyst that can generate (produce) radicals under mild conditions. In order to achieve the above object, a first radical generating catalyst according to the first aspect of the present invention is characterized in that it includes ammonium and/or a salt thereof. A second radical generating catalyst according to the first aspect of the present invention is characterized in that it includes an organic compound having Lewis acidic properties and/or Brønsted acidic properties.